PMID- 10195616
OWN - NLM
STAT- MEDLINE
DCOM- 19990602
LR  - 20190728
IS  - 0264-410X (Print)
IS  - 0264-410X (Linking)
VI  - 17
IP  - 9-10
DP  - 1999 Mar 5
TI  - Biodegradable microspheres containing influenza A vaccine: immune response in 
      mice.
PG  - 1065-73
AB  - A monovalent influenza split vaccine was microencapsulated in 
      poly(D,L-lactic-co-glycolic acid) (PLGA) and ABA triblock copolymers using a 
      W/O/W double emulsion technique. To stabilize the antigen, influenza vaccine was 
      also coencapsulated with liposomes. Antigen release from microspheres was 
      determined in vitro using a hemagglutinin-specific ELISA. PLGA-microspheres with 
      liposomes released immunoreactive hemagglutinin in a pulsatile manner, a 
      preferred feature for the development of a single dose vaccine delivery system. 
      Influenza hemagglutinin specific IgG and neutralizing antibody responses were 
      studied in BALB/c mice following subcutaneous injection of different microsphere 
      preparations. PLGA-microspheres elicited a significantly higher primary IgG 
      response compared to nonencapsulated antigen. ABA-microspheres seemed to be less 
      immunogenic than PLGA-microspheres based on the IgG antibody response, however, 
      similar levels of neutralizing antibodies were observed after eight weeks with 
      both polymers. Entrapment of the antigen in liposomes prior to microencapsulation 
      did not further enhance the immune response. The immunopotentating effect of the 
      antigen-loaded microspheres was prominently enhanced when they were given as 
      suspension in fluid antigen, suggesting that free antigen may serve as priming 
      and microencapsulated antigen as booster dose. Eight weeks after a single 
      subcutaneous immunization with PLGA or ABA-microspheres neutralizing antibodies 
      were as high as those obtained after two subcutaneous administrations of fluid 
      vaccine four weeks apart. Microencapsulated influenza antigen may have potential 
      for a single dose vaccine delivery system with adjuvant properties.
FAU - Hilbert, A K
AU  - Hilbert AK
AD  - Department of Pharmaceutics and Biopharmacy, Philipps-University, Marburg, 
      Germany.
FAU - Fritzsche, U
AU  - Fritzsche U
FAU - Kissel, T
AU  - Kissel T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - Vaccine
JT  - Vaccine
JID - 8406899
RN  - 0 (Antibodies, Viral)
RN  - 0 (Biocompatible Materials)
RN  - 0 (Influenza Vaccines)
RN  - 0 (Polymers)
RN  - 1SIA8062RS (Polylactic Acid-Polyglycolic Acid Copolymer)
RN  - 26009-03-0 (Polyglycolic Acid)
RN  - 33X04XA5AT (Lactic Acid)
SB  - IM
MH  - Animals
MH  - Antibodies, Viral/biosynthesis
MH  - Biocompatible Materials
MH  - Biodegradation, Environmental
MH  - Female
MH  - Influenza A virus/*immunology
MH  - Influenza Vaccines/*administration & dosage/*immunology
MH  - Lactic Acid
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Microspheres
MH  - Polyglycolic Acid
MH  - Polylactic Acid-Polyglycolic Acid Copolymer
MH  - Polymers
EDAT- 1999/04/09 00:00
MHDA- 1999/04/09 00:01
CRDT- 1999/04/09 00:00
PHST- 1999/04/09 00:00 [pubmed]
PHST- 1999/04/09 00:01 [medline]
PHST- 1999/04/09 00:00 [entrez]
AID - S0264-410X(98)00323-5 [pii]
AID - 10.1016/s0264-410x(98)00323-5 [doi]
PST - ppublish
SO  - Vaccine. 1999 Mar 5;17(9-10):1065-73. doi: 10.1016/s0264-410x(98)00323-5.